Metastatic Non-Cutaneous Melanoma
1 clinical trials · Condition
◉ Watch Metastatic Non-Cutaneous Melanoma
| Record | Firm | Date |
|---|---|---|
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (NCT02506153) | National Cancer Institute (NCI) | 2015-11-10 |
Track Metastatic Non-Cutaneous Melanoma automatically
Every clearance here is in the API, with alerts when new ones post.